INTRODUCTION: Improved outcome measures are essential to efficiently screen the growing number of potential amyotrophic lateral sclerosis (ALS) therapies. METHODS: This longitudinal study of 100 (70 male) participants with ALS compared Accurate Test of Limb Isometric Strength (ATLIS), using a fixed, wireless load cell, with ALS Functional Rating Scale-Revised (ALSFRS-R) and vital capacity (VC). RESULTS: Participants enrolled at 5 U.S. sites. Data were analyzed from 66 participants with complete ATLIS, ALSFRS-R, and VC data over at least 3 visits. Change in ATLIS was less variable both within- and among-person than change in ALSFRS-R or VC. Additionally, participants who had normal ALSFRS-R arm and leg function averaged 12 to 32% below expected strength values measured by ATLIS. CONCLUSIONS: ATLIS was more sensitive to change than ALSFRS-R or VC and could decrease sample size requirements by approximately one-third. The ability of ATLIS to detect prefunctional change has potential value in early trials. Muscle Nerve 56: 710-715, 2017.
INTRODUCTION: Improved outcome measures are essential to efficiently screen the growing number of potential amyotrophic lateral sclerosis (ALS) therapies. METHODS: This longitudinal study of 100 (70 male) participants with ALS compared Accurate Test of Limb Isometric Strength (ATLIS), using a fixed, wireless load cell, with ALS Functional Rating Scale-Revised (ALSFRS-R) and vital capacity (VC). RESULTS:Participants enrolled at 5 U.S. sites. Data were analyzed from 66 participants with complete ATLIS, ALSFRS-R, and VC data over at least 3 visits. Change in ATLIS was less variable both within- and among-person than change in ALSFRS-R or VC. Additionally, participants who had normal ALSFRS-R arm and leg function averaged 12 to 32% below expected strength values measured by ATLIS. CONCLUSIONS: ATLIS was more sensitive to change than ALSFRS-R or VC and could decrease sample size requirements by approximately one-third. The ability of ATLIS to detect prefunctional change has potential value in early trials. Muscle Nerve 56: 710-715, 2017.
Authors: Paul Mehta; D Kevin Horton; Edward J Kasarskis; Ed Tessaro; M Shira Eisenberg; Susan Laird; John Iskander Journal: MMWR Morb Mortal Wkly Rep Date: 2017-12-22 Impact factor: 17.586
Authors: Jaap N E Bakers; Leonard H van den Berg; Toju G Ajeks; Maxine J Holleman; Jill Verhoeven; Anita Beelen; Johanna M A Visser-Meily; Ruben P A van Eijk Journal: J Neurol Date: 2020-12-23 Impact factor: 4.849
Authors: Robert H Baloh; J Patrick Johnson; Pablo Avalos; Peggy Allred; Soshana Svendsen; Genevieve Gowing; Kristina Roxas; Amanda Wu; Becky Donahue; Sheryl Osborne; George Lawless; Brandon Shelley; Koral Wheeler; Carolyn Prina; Dana Fine; Tami Kendra-Romito; Haniah Stokes; Vicki Manoukian; Abirami Muthukumaran; Leslie Garcia; Maria G Bañuelos; Marlesa Godoy; Catherine Bresee; Hong Yu; Doniel Drazin; Lindsey Ross; Robert Naruse; Harish Babu; Eric A Macklin; Ashley Vo; Ashraf Elsayegh; Warren Tourtellotte; Marcel Maya; Matthew Burford; Frank Diaz; Chirag G Patil; Richard A Lewis; Clive N Svendsen Journal: Nat Med Date: 2022-09-05 Impact factor: 87.241
Authors: Massimo Russo; Christian Lunetta; Riccardo Zuccarino; Gian L Vita; Maria Sframeli; Andrea Lizio; Stefania La Foresta; Cristina Faraone; Valeria A Sansone; Giuseppe Vita; Sonia Messina Journal: Sci Rep Date: 2020-09-23 Impact factor: 4.379